Ask AI

Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Get an expert&rsquo s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this program which features a series of ClinicalThought&trade commentaries on emerging clinical data managing immune-related adverse events and key biomarkers of response.

Share

Program Content

Activities

ICIs in Gastric/GEJ
How I Use Checkpoint Inhibitors in Later-line Advanced Gastric/GEJ Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2019

Expires: July 16, 2020

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb